03281nas a2200589   4500000000100000008004100001260001300042653001500055653001000070653000900080653002600089653002400115653002200139653003800161653001100199653001600210653001100226653001200237653002400249653000900273653001600282653002500298653002500323653001700348653001600365100001500381700001000396700001200406700001700418700001400435700001500449700001000464700001300474700001700487700001300504700001300517700001300530700001400543700001800557700001200575700001200587700001500599700001500614700002200629245019200651856007200843300001000915490000700925050001700932520172800949022001402677       2011                            d  c2011 Feb10aAdolescent10aAdult10aAged10aAntibodies, Bacterial10aAntigens, Bacterial10aBlotting, Western10aEnzyme-Linked Immunosorbent Assay10aFemale10aGlycolipids10aHumans10aleprosy10aLipopolysaccharides10aMale10aMiddle Aged10aMycobacterium leprae10aRecombinant Proteins10aTime Factors10aYoung Adult1 aSpencer JS1 aKim H1 aWheat W1 aChatterjee D1 aBalagon M1 aCellona RV1 aTan E1 aGelber R1 aSaunderson P1 aDuthie M1 aReece ST1 aBurman W1 aBelknap R1 aMac Kenzie WR1 aGeluk A1 aOskam L1 aDockrell H1 aBrennan PJ1 aIdeal Consortium 00aAnalysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy.  uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067349/pdf/0472-10.pdf  a260-70 v18  aSPENCER2011a3 a<p>A simple serodiagnostic test based on the Mycobacterium leprae-specific phenolic glycolipid I(PGL-I), for individuals with leprosy is nearly universally positive in leprosy patients with high bacillary loads but cannot be used as a stand-alone diagnostic test for the entire spectrum of the disease process. For patients with early infection with no detectable acid-fast bacilli in lesions or with low or no antibody titer to PGL-I, as in those at the tuberculoid end of the disease spectrum, this diagnostic approach has limited usefulness. To identify additional M. leprae antigens that might enhance the serological detection of these individuals, we have examined the reactivity patterns of patient sera to PGL-I, lipoarabinomannan (LAM), and six recombinant M. leprae proteins (ML1877, ML0841, ML2028, ML2038, ML0380, and ML0050) by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Overall, the responses to ML2028 (Ag85B) and ML2038 (bacterioferritin) were consistently high in both multibacillary and paucibacillary groups and weak or absent in endemic controls, while responses to other antigens showed considerable variability, from strongly positive to completely negative. This analysis has given a clearer understanding of some of the differences in the antibody responses between individuals at opposite ends of the disease spectrum, as well as illustrating the heterogeneity of antibody responses toward protein, carbohydrate, and glycolipid antigens within a clinical group. Correlating these response patterns with a particular disease state could allow for a more critical assessment of the form of disease within the leprosy spectrum and could lead to better patient management.</p>  a1556-679X